A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention.

Trial Profile

A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs AMG-301 (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 09 Aug 2018 Planned End Date changed from 18 Dec 2018 to 4 Feb 2019.
    • 09 Aug 2018 Planned primary completion date changed from 31 Aug 2018 to 16 Oct 2018.
    • 09 Aug 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top